What You Should Know:
– Corundum Neuroscience, formerly Joy Ventures launches a new neuroscience-focused venture builder and fund to spur neuroscience research and innovation.
– The newly rebranded Corundum Neuroscience works with researchers and entrepreneurs with commercially applicable ideas to build and grow companies developing innovative solutions spanning a range of health and disease areas, including anxiety, depression, PTSD, chronic pain, sleep and neurodegenerative disorders.
Corundum Neuroscience’s Lab-to-Life Model
Corundum Neuroscience’s “lab-to-life” model supports the entire innovation journey, from early research stages to commercialization, with the goal of improving people’s daily lives globally. The company identifies research, enabling technologies, and early-stage startups with high commercial potential and societal impact and aims to bridge the gap between research and market launch in the neuroscience technology domain. Corundum Neuroscience operates under its parent company, Corundum Innovation, which provides comprehensive support for research funding, venture investment services, and business consulting. They have also established the Corundum Convergence Institute (CCI), a non-profit organization offering research grants in neuroscience, systems biology, and AI-based scientific exploration.
Corundum Neuroscience’s portfolio includes companies like Gray Matters Health, Myndlift, and NYX Technologies, focusing on digital self-neuromodulation therapies, therapist-guided neuro-feedback, and personalized sleep optimization.